Immunoglobulin and other proteins in the
cerebrospinal fluid of patients with Alzheimer’s
disease

HM CHAPEL,* MM ESIRI,† GK WILCOCK†

From the *Immunopathology Department, John Radcliffe Hospital, Oxford, and †Neuropathology and
Geriatrics Departments, Radcliffe Infirmary, Oxford

SUMMARY  Immunoglobulin has been measured and studied electrophoretically in cerebrospinal
fluid (CSF) from 14 patients with Alzheimer’s disease and 25 undemented controls. Presence or
absence of the diagnosis of Alzheimer’s disease was confirmed histologically, as these were
postmortem specimens. There was no increased incidence of oligoclonal IgG bands in either
group, and no significant differences in the levels of IgG and albumin. Non-immunoglobulin
bands were found in the gamma region in some samples from Alzheimer’s disease patients
and controls; such bands are not found in the CSF from younger patients. There was a significantly
increased incidence of double transferrin and double tau protein bands in the Alzheimer’s group,
suggesting that further studies of genetic markers might be worthwhile.

Electrophoretic examination of immunoglobulin in
the cerebrospinal fluid (CSF) of patients with pro-
gressive dementia has been performed in three
studies. Such studies are of interest for the light they
may throw on the aetiology of Alzheimer’s disease,
the commonest cause of senile and presenile demen-
tia. Williams et al1 claimed to find oligoclonal IgG in
the CSF of five of eight samples examined from
patients with presenile dementia. They suggested
that this disease may be due to an infectious agent,
since other diseases known to be due to infectious
agents—such as syphilis and subacute sclerosing
panencephalitis—are associated with the presence
of oligoclonal IgG bands in the CSF. Other studies
have failed to show oligoclonal bands in CSF from
demented patients.2,3

We report here an electrophoretic study of CSF
obtained from the cerebral ventricles of a group of
patients at necropsy. The patients were prospect-
ively assessed for the presence or absence of
dementia during life, and histological examination
of the brain at necropsy confirmed or refuted the
clinical diagnosis of Alzheimer’s disease. There was
no increased incidence of oligoclonal IgG bands in
the CSF from patients with Alzheimer’s disease
compared with controls. Non-immunoglobulin pro-
teins, however, were different in the CSF samples
from the two types of patients.

Accepted for publication 1 March 1984

Material and methods

Ventricular CSF was obtained at necropsy from 42
patients: 17 of these patients were known from the
performance of a mental test score to have been
demented during life and 25 were undemented con-
trols. Of the 17 demented patients, 14 had the diag-
nosis of Alzheimer’s disease confirmed by pathol-
ogical examination of the brain. These brains con-
tained numerous argyrophilic plaques and
neurofibrillary tangles in frontal and temporal lobe
neocortex and hippocampus. One brain also showed
evidence of mild cerebrovascular disease, and one
contained a few small inactive multiple sclerosis pla-
ques. Three of the brains from demented patients
showed evidence of cerebrovascular disease only,
and these patients were then reclassified to the con-
trol group. Of the 25 undemented patients, 14 had
no relevant central nervous system disease, eight
had cerebrovascular disease, and three had evidence
of other central nervous system disease (mild hy-
drocephalus, old contusions, or Parkinson’s disease).

Some of these patients have been the subjects of
earlier studies.4–8 The interval between death and
postmortem examination (during which the bodies
were refrigerated) varied between 8 h and four days
and did not differ between the groups studied. Mean
ages of patients in the two groups were comparable.

CSF specimens were kept frozen until the time of
assay. IgG and albumin were measured nephelometrically, and polyacrylamide gel electrophoresis was performed according to the method of Thompson et al. Gels were stained with both Comassie blue and naphthalene black. Eight specimens in which haemoglobin-haptoglobin complexes, indicative of blood contamination, were detected were excluded from the electrophoretic part of the study (two patients with Alzheimer’s disease and six controls).

All the CSF analyses were done without knowledge of the clinical and pathological diagnoses.

Serum samples, obtained at postmortem examination, were available for seven Alzheimer’s disease patients and 23 controls.

Results

Concentrations of IgG and albumin in the CSF of patients with Alzheimer’s disease and of controls were unremarkable. The IgG:albumin ratios in CSF from patients with Alzheimer’s disease ranged from 9 to 30% (mean 22%; n = 14). The range in control patients was wider (5–54%), but the mean was similar (25%; n = 28). One in four of the Alzheimer patients had a CSF IgG:albumin ratio greater than 25%; this proportion was similar in the control group (see Table 1).

Serum IgG and albumin concentrations were widely variable in patients with Alzheimer’s disease and in controls, but there was no significant difference in these values between the two groups. The wide variation in the serum concentrations made calculation of IgG indices unreliable.

Electrophoretic analysis showed no excess of oligoclonal bands in Alzheimer’s disease CSF compared with controls (Table 2). Oligoclonal IgG bands were found in the CSF of two patients with Alzheimer’s disease (17%) compared with six of the controls (27%). The presence of oligoclonal bands was not correlated with a raised IgG:albumin ratio in CSF (Table 1). There was detectable IgA in the γ 1 position in three patients with Alzheimer’s disease

Table 1  Comparison of nephelometric and electrophoretic findings between patients and controls.*

<table>
<thead>
<tr>
<th>No of patients</th>
<th>Oligoclonal bands</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Present</td>
</tr>
<tr>
<td>Controls</td>
<td></td>
</tr>
<tr>
<td>CSF IgG:albumin ratio &gt; 25%</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>&lt; 25%</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with Alzheimer’s disease</td>
<td></td>
</tr>
<tr>
<td>CSF IgG:albumin ratio &gt; 25%</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>&lt; 25%</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*CSF contaminated with blood was excluded (see Material and methods).

and in six of the control group, but the difference was not significant.

Electrophoretic examination of other proteins in the CSF showed acute inflammatory proteins in samples from 11 of 12 patients with Alzheimer’s disease (92%) compared with 17 of 22 control samples (77%), a difference that is not significant. Single bands in the γ 3 and γ 5 positions were found in some samples from patients with Alzheimer’s disease and controls. These did not appear to be IgG because they stained equally with Comassie blue and naphthalene black. A higher incidence of double transferrin and double tau protein bands was found in CSF samples from the Alzheimer’s disease group compared with those of the control group (Table 2). Of the samples from patients with Alzheimer’s disease, 42% showed a double transferrin band (controls 4%; p < 0.02) and 25% a double α,-antitrypsin band (controls 4%; NS). The presence of these bands did not correlate with delay in performing the postmortem examination or with drug treatment of the patients.

Discussion

In this study oligoclonal bands in CSF were found in a proportion of patients with Alzheimer’s disease

Table 2  Comparison of ages and CSF electrophoretic findings between patients and controls*  

<table>
<thead>
<tr>
<th></th>
<th>Patients with Alzheimer’s disease</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 12)</td>
<td>(n = 22)</td>
</tr>
<tr>
<td>Age range (yr)</td>
<td>51–93</td>
<td>68–99</td>
</tr>
<tr>
<td>mean (yr)</td>
<td>88</td>
<td>81</td>
</tr>
<tr>
<td>Oligoclonal IgG</td>
<td>2 (17%)</td>
<td>6 (27%)</td>
</tr>
<tr>
<td>Diffuse IgA</td>
<td>3 (25%)</td>
<td>6 (27%)</td>
</tr>
<tr>
<td>Acute inflammation</td>
<td>11 (92%)</td>
<td>17 (77%)</td>
</tr>
<tr>
<td>γ 3</td>
<td>8 (66%)</td>
<td>16 (72%)</td>
</tr>
<tr>
<td>γ 5</td>
<td>4 (33%)</td>
<td>4 (18%)</td>
</tr>
<tr>
<td>Double transferrin</td>
<td>5 (42%)</td>
<td>1 (4%)</td>
</tr>
<tr>
<td>Double α,-antitrypsin</td>
<td>3 (25%)</td>
<td>1 (4%)</td>
</tr>
</tbody>
</table>

*CSF contaminated with blood was excluded. (See Material and methods).
Immunoglobulin and other proteins in the cerebrospinal fluid of patients with Alzheimer's disease

The importance of the presence of oligoclonal bands in 17% of the patients with Alzheimer's disease and 27% of control patients is uncertain. The latter group included some patients with old or recent strokes and cerebral infarcts at postmortem examination of the brain, and it is of interest that oligoclonal bands have been found in CSF of stroke patients before. Whatever the cause of the oligoclonal bands in our patients' CSF, this study does not support the view that Alzheimer's disease is caused by an infectious agent capable of stimulating an immune response in the central nervous system.

We found an unexpectedly high incidence of unusual CSF bands representing non-immunoglobulin protein in this study. Our view that these bands are not immunoglobulin rests on the finding that they were stained equally well with both Commassie blue and naphthalene black. Some of the earlier studies of CSF in dementia have not used both stains and it is possible that the bands reported by Williams et al were haptoglobin rather than immunoglobulin.

A band in the γ 3 position was seen in CSF from 66% of patients with Alzheimer's disease and 72% of control patients, and a band in the γ 5 position was seen in 25% of patients with Alzheimer's disease and 78% of controls. Bands in these positions have not been seen in CSF samples from younger patients in our laboratory. Whether they represent serum derived or central nervous system derived proteins remains to be determined. There was no obvious correlation with delay before necropsy but further work will also be required to discover whether these bands may be related to autolysis. Acute inflammatory proteins were often seen in samples of CSF from patients with Alzheimer's disease (92%) and controls (77%), indicating increased vascular permeability of the blood-brain barrier in both groups.

Double transferrin and double tau proteins were found in the samples from patients with Alzheimer's disease more frequently than those of controls (Table 2). This finding suggests that it may be of some interest to search for other genetic markers in CSF of patients with Alzheimer's disease. HLA typing has so far proved to be disappointing as no specific marker associated with Alzheimer's disease has been shown, but studies of complement C4 allotypes have suggested an association between a C4 B2 variant and Alzheimer's disease. Other markers may well exist and are not necessarily confined to chromosome 6.

The advantage of studying postmortem CSF samples has been that it has been possible to study a group of patients with histologically confirmed Alzheimer's disease. Use of postmortem samples of CSF may, however, introduce distortions in patterns of proteins that are due to postmortem autolysis. Nevertheless, the significant differences in the incidences of some protein bands in this series between patients with Alzheimer's disease and controls is encouraging and suggests that further studies of CSF and serum from such patients would be worthwhile.

This work was supported by a grant from the Locally Organised Research Scheme, Oxford RHA.

We are grateful to Mrs J Wilkinson and Mr D Smith for their excellent technical assistance, and to Dr EJ Thompson of the Institute of Neurology, London.

References


Requests for reprints to: Dr HM Chapel, Department of Immunology, John Radcliffe Hospital, Oxford.
Immunoglobulin and other proteins in the cerebrospinal fluid of patients with Alzheimer's disease.
H M Chapel, M M Esiri and G K Wilcock

doi: 10.1136/jcp.37.6.697

Updated information and services can be found at:
http://jcp.bmj.com/content/37/6/697

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/